Injectable ramp-up is the engine, with Q1 momentum building as utilization and US commercialization gain traction. The rich price already banks it all landing.
Overall read
5.7/10
Priced ahead of it
The three reads · this quarter
Injectable ramp-up is the engine, with Q1 momentum building as utilization and US commercialization gain traction. The rich price already banks it all landing.
Overall read
5.7/10
Priced ahead of it
The three reads · this quarter
The standing reads · change less often
Moat
Moderate edge
Niche fermentation expertise and high entry barriers support a narrow moat.
Key variables
5 tracked
lead: Capacity utilizationUnit 3 remains the main growth engine with significant headroom; Unit 4 is still nascent and will require aggressive ramp-up to meaningfully impact revenue.
Walk the talk
Not enough data
as of Q1 FY27Injectable facility ramp-up with peak potential of INR 600 Cr is key near-term growth driver.
Latest · newest first
No material exchange filings in the last 60 days. Latest scored quarter: Q1FY27.
Open the Exchange Desk1 of 1 guidance items delivered on time
Where it sits